Research and Clinical Trials on Clonazepam (Klonopin, Rivotril)

Clonazepam (Klonopin, Rivotril) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Clonazepam (Klonopin, Rivotril).

• Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
  Status: Recruiting, Condition Summary: Epilepsy
• Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
  Status: Recruiting, Condition Summary: REM Behavior Disorder; Parkinsonism
• Bioavailability Study of Clonazepam ODT Under Fasting Conditions
  Status: Completed, Condition Summary: To Determine Bioequivalence Under Fasting Conditions
• Bioavailability Study of Clonazepam Tablets Under Fasting Conditions
  Status: Completed, Condition Summary: To Determine Bioequivalence Under Fasting Conditions
• Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
  Status: Recruiting, Condition Summary: Social Phobia
• Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
  Status: Enrolling by invitation, Condition Summary: Unverricht-Lundborg Syndrome
• Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder
  Status: Completed, Condition Summary: Post Traumatic Stress Disorder
• Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
  Status: Completed, Condition Summary: Panic Disorder
• Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
  Status: Recruiting, Condition Summary: Epilepsy; Mental Retardation
• Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
  Status: Recruiting, Condition Summary: Status Epilepticus
• Therapies for Treatment-Resistant Panic Disorder Symptoms
  Status: Active, not recruiting, Condition Summary: Panic Disorder

 

Get These Clinical Trials as a Newsfeed

Clonazepam:             

Current Research Literature on Clonazepam (Klonopin, Rivotril)

Here are abstracts for some of the latest research articles to have appeared on Clonazepam (Klonopin, Rivotril):

A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.

Eur Psychiatry. 2008 Sep 5;
Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL
BACKGROUND: Both psychodynamic group therapy (PGT) and clonazepam are used as treatment strategies in reducing symptoms of generalized social anxiety disorder (GSAD). However, many individuals remain symptomatic after treatment with PGT or clonazepam. METHOD: Fifty-eight adult outpatients with a diagnosis of GSAD according to DSM-IV were randomized to 12weeks PGT plus clonazepam or clonazepam. The Clinical Global Impression-Improvement (CGI-I) Scale was the primary efficacy measure. Secondary efficacy measures included the Liebowitz Social Anxiety Scale (LSAS) total score, the World Health Organization Instrument to Assess Quality of Life-Brief (WHOQOL-Bref) Scale and the Beck Depression Inventory (BDI). RESULTS: CGI-I data from 57 patients (intent-to-treat population) showed that patients who received PGT plus clonazepam presented significantly greater improvement than those who received clonazepam (P=0.033). There were no significant differences between the two groups in the secondary efficacy measures. CONCLUSIONS: Our study suggests that the combination of PGT with clonazepam may be a promising strategy for the treatment of GSAD, regarding gains in the global functioning. However the present study failed to detect more specific changes in social anxiety symptomatology between the two groups.

Behavioral disinhibition, suicidal ideation, and self-mutilation related to clonazepam.

J Child Adolesc Psychopharmacol. 2008 Aug; 18(4): 409
Kandemir H, Yumru M, Kul M, Kandemir SB

Mechanisms of unmodified CdSe quantum dot-induced elevation of cytoplasmic calcium levels in primary cultures of rat hippocampal neurons.

Biomaterials. 2008 Nov; 29(33): 4383-91
Tang M, Wang M, Xing T, Zeng J, Wang H, Ruan DY
Quantum dots (QDs) have shown great promise for applications in biology and medicine, which is being challenged by their potential nanotoxicity. Reactive oxygen species (ROS) produced by QDs are believed to be partially responsible for QD cytotoxicity. Cytoplasmic Ca(2+) plays an important role in the development of ROS injury. Here we found unmodified cadmium selenium (CdSe) QDs could elevate cytoplasmic calcium levels ([Ca(2+)](i)) in primary cultures of hippocampal neurons, involved both extracellular Ca(2+) influx and internal Ca(2+) release. More specifically, verapamil and mibefradil (L-type and T-type calcium channels antagonists, respectively) failed to prevent extracellular Ca(2+) influx under QD insult, while omega-conotoxin (N-type antagonist) could partially block this Ca(2+) influx. Surprisingly, this Ca(2+) influx could be well blocked by voltage-gated sodium channels (VGSCs) antagonist, tetrodotoxin (TTX). QD-induced internal Ca(2+) release could be avoided by clonazepam, a specific inhibitor of mitochondrial sodium-calcium exchangers (MNCX), and also by TTX. Furthermore, dantrolene, an antagonist of ryanodine (Ry) receptors in endoplasmic reticulum (ER), almost abolished internal Ca(2+) release, while 2-APB [inositol triphosphate (IP(3)) receptors antagonist] failed to block this Ca(2+) release, indicating that released Ca(2+) from mitochondria, which was induced by extracellular Na(+) influx, further triggered much more Ca(2+) release from ER. Our results imply that more research on the biocompatibility and biosafety of QD is both warranted and necessary.

Clonazepam for chemotherapy-induced nausea and vomiting (CINV).

Anticancer Res. 2008 Jul-Aug; 28(4C): 2433-6
Koga M, Nakadozono M, Nukariya K, Nogi H, Kobayashi T, Nakayama K
BACKGROUND: A 51-year-old woman experienced refractory chemotherapy-induced nausea and vomiting (CINV) in spite of extensive antiemetic therapy, including 5-HT3 antagonists, corticosteroids, dopamine antagonists and antihistamines. CASE REPORT: We administered the patient clonazepam. After taking clonazepam, the patient fully recovered from the nausea and vomiting and never experienced them again. CONCLUSION: Clonazepam may be useful in the control of CINV. We believe that clonazepam contributed to the favorable outcome by expressing an anxiolytic and an anticonvulsant effect on myoclonus. The efficacy of clonazepam in this indication of prevention of CINV warrants further investigation.

Clonazepam Oral Droplets for the Treatment of Acute Epileptic Seizures.

Drug Dev Ind Pharm. 2008 Aug 13; 1-5
Sakata O, Onishi H, Machida Y
Oral droplet formulations of clonazepam (CZ) were developed to examine their potentials as an alternative to i.v. administration for the treatment of acute epileptic seizures. Propylene glycol containing 2.5% (wt/wt) CZ with or without 5.0% (wt/wt) oleic acid (OA) was prepared as a solution by heating at 90 degrees C and subsequently lowering the temperature to 30 degrees C. The droplet (20 muL) was administered to the oral cavity between the lower gum and bottom lip before CZ precipitation started. With a droplet of propylene glycol loaded with 2.5% (wt/wt) CZ and 5.0% (wt/wt) OA, the plasma concentration reached 20 ng/mL (minimal effective concentration) within 10 min and was maintained between 20 and 60 ng/mL, less than a toxic level, for a period of 60 min. For a droplet of propylene glycol loaded only with CZ at 2.5% (wt/wt), it took more than 15 min for the plasma concentration to reach 20 ng/mL. It is suggested that a droplet of CZ/OA/propylene glycol (2.5:5.0:92.5, wt/wt) might be useful as an alternative to i.v. injection of CZ for the treatment of acute epileptic seizures.